DIVISLAB's weekly performance was disappointing, with a return of -1.2% and a Sharpe Ratio of -0.09, indicating poor risk-adjusted returns. The stock's volatility was high at 62.08%, making it a risky investment this week. Compared to its peers, DIVISLAB outperformed DRREDDY and CIPLA but underperformed SUNPHARMA. Overall, the stock's high volatility and negative returns make it a cautionary investment.

[Volatility: 62.08%]